PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15473914-0	2004	Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson"s disease, and downregulates the dopamine transporter via the D3 receptor.	Pramipexole	9-20	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	110-130	
25511804-4	2015	We show that prolonged administration of pramipexole (0.1mg/kg/day, 6 to 21 days), a preferential D3R agonist, leads to a decrease in DA uptake in mouse striatum that reflects a reduction in DAT affinity for DA in the absence of any change in DAT density or subcellular distribution.	Pramipexole	41-52	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	191-194	
25511804-4	2015	We show that prolonged administration of pramipexole (0.1mg/kg/day, 6 to 21 days), a preferential D3R agonist, leads to a decrease in DA uptake in mouse striatum that reflects a reduction in DAT affinity for DA in the absence of any change in DAT density or subcellular distribution.	Pramipexole	41-52	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	243-246	
15473914-2	2004	We also determined whether subchronic treatment with pramipexole regulates dopamine transporter function, thereby reducing intracellular transport of the active metabolite of MPTP, 1-methyl-4-phenylpyridinium (MPP+).	Pramipexole	53-64	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	75-95	
15473914-9	2004	MPTP- induced loss of striatal innervation, as measured by DAT-immunoreactivity, was partially prevented by pramipexole, but not with regard to TH-IR.	Pramipexole	108-119	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	59-62	
15473914-10	2004	Pramipexole also reduced DAT- immunoreactivity in non-MPTP treated mice.	Pramipexole	0-11	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	25-28